Antifungal News and Research

RSS

Study explains how rapamycin also causes insulin resistance

A Penn- and MIT-led team explained how rapamycin, a drug that extends mouse lifespan, also causes insulin resistance. The researchers showed in an animal model that they could, in principle, separate the effects, which depend on inhibiting two protein complexes, mTORC1 and mTORC2, respectively.

30 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

UI chemists debunk misconception about amphotericin

With one simple experiment, University of Illinois chemists have debunked a widely held misconception about an often-prescribed drug.

17 Jan 2012

Study examines prevalence of Fusarium in bathroom sink drains

A study examining the prevalence of the fungus Fusarium in bathroom sink drains suggests that plumbing systems may be a common source of human infections.

22 Dec 2011

Radioimmunotherapy shows promise against fungal diseases

Invasive fungal infections (IFI) are a major threat to individuals with cancer, transplants, HIV, and other conditions that weaken their immune system. New research has shown that radioimmunotherapy (RIT) could be a promising avenue for development of new types of treatment of fungal diseases, according to a paper published by scientists of the Joint Research Centre (JRC) in collaboration with other researchers.

2 Dec 2011

Cell-penetrating or antimicrobial peptides could treat atopic eczema

Scientists have found that a strain of yeast implicated in inflammatory skin conditions, including eczema, can be killed by certain peptides and could potentially provide a new treatment for these debilitating skin conditions.

24 Nov 2011

NIH awards LSUHSC $9 million grant to develop pneumonia vaccine

Dr. Judd Shellito, Chief of the Section of Pulmonary and Critical Care Medicine at LSU Health Sciences Center New Orleans, has been awarded approximately $9 million in grant funding to develop a vaccine against Pneumocystis, an important cause of pneumonia in people with HIV infection. This potentially fatal illness is the most common serious opportunistic infection in people with HIV.

7 Oct 2011

Additional data on safety, tolerability of Cempra's solithromycin to be presented at 51st ICAAC

Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.

17 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

Insight Pharmaceuticals announces acquisition of MONISTAT business from McNEIL-PPC

Insight Pharmaceuticals, a portfolio company of Swander Pace Capital, announced today that it has acquired the MONISTAT North American brand portfolio from McNEIL-PPC, Inc.

31 Aug 2011

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

The Food and Drug Administration has cleared a new diagnostic test that will help save the lives of hundreds of thousands of AIDS patients stricken with cryptococcosis, a fungal meningitis.

25 Aug 2011

Novel link between two receptors mediates fungal recognition in macrophages

Whitehead Institute researchers have uncovered a novel association between two fungal recognition receptors on the surface of certain immune cells, called macrophages.

9 Aug 2011

NIH selects Viamet's novel antifungal compound for inclusion in the TRND program

Viamet Pharmaceuticals, Inc. announced today that one of its novel antifungal compounds has been selected for inclusion in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Diseases (TRND) program.

29 Jul 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

Itraconazol may keep prostate cancer from worsening and delay need for chemotherapy in men

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease.

3 Jun 2011

Antimicrobials in plastics

The demand of antimicrobials in the plastic business is growing. SANITIZED AG is following a strategy of direct commercialisation of its products in the Plastic Market. Its clients profit from a short time to market and professional consulting over the whole project process.

31 May 2011

FDA warns consumers about look like antimicrobial dietary supplements

The FDA is warning consumers not to use products marketed as dietary supplements that also claim to be antimicrobial (antibiotic, antifungal or antiviral) drugs. These illegal products are falsely promoted with claims to treat illnesses such as upper respiratory infections, sinusitis, pneumonia, bronchitis and the common cold.

16 May 2011

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei Group Corporation, the biopharmaceutical company, today announces that Sosei Co., Ltd., its wholly owned Japanese subsidiary, acquired development and commercialization rights to Loramyc (miconazole Lauriad) in Japan from BioAlliance Pharma.

11 May 2011

New test can diagnose deadly human fungal infections

Deadly human fungal infections caused by certain strains of Aspergillus fungi appear to be developing resistance to current drug treatments at an alarming rate, say scientists.

5 May 2011